What is retatrutide and why is it called a triple agonist?
Retatrutide is an investigational peptide developed by Eli Lilly that simultaneously activates three hormone receptors: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The dual-agonist tirzepatide (which Lilly also developed) activates GIP and GLP-1 receptors. Retatrutide extends this by adding glucagon receptor activation as a third mechanism.
Each receptor plays a distinct metabolic role. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation amplifies insulin secretion and may affect adipocyte metabolism. Glucagon receptor activation is the addition that distinguishes retatrutide from its predecessors: glucagon classically promotes glucose release from the liver (glycogenolysis and gluconeogenesis) and — at the dose levels being studied here in combination with GLP-1/GIP activity — may increase resting energy expenditure by activating thermogenic pathways.
The theoretical promise of the triple mechanism is that adding glucagon receptor agonism to the GIP/GLP-1 combination may increase energy expenditure (calories burned at rest) while the GLP-1 and GIP components manage appetite and insulin signaling. Whether this produces a clinically meaningful additive effect with an acceptable safety profile is exactly what phase 3 trials are designed to answer.
What did the phase 2 trial data show?
Retatrutide published phase 2 results in the New England Journal of Medicine in 2023. The trial was a randomized, double-blind, placebo-controlled study in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity.
Key findings from the phase 2 obesity trial:
- Weight reduction at 24 weeks: Participants receiving the highest dose (12 mg weekly) had a mean weight reduction of approximately 17.5% at 24 weeks. Extrapolated trajectories suggested continued loss beyond the trial period.
- Dose-dependent response: Lower doses (1 mg, 4 mg, 8 mg) showed progressively greater effects, suggesting an active dose-response relationship at doses studied.
- Side effects: GI side effects (nausea, vomiting, diarrhea) were the most common adverse events, consistent with the GLP-1 class. Rates were broadly comparable to tirzepatide at similar weight-loss magnitudes.
- Heart rate: Retatrutide increased resting heart rate more than semaglutide or tirzepatide in early data, an effect attributed to glucagon receptor activation. The clinical significance of this increase is being evaluated in phase 3 cardiovascular outcome trials.
A parallel phase 2 trial in patients with type 2 diabetes also showed significant HbA1c reductions alongside weight loss, published concurrently in The Lancet.
Retatrutide’s triple mechanism is genuinely promising in phase 2, but promising phase 2 data is not the same as a proven, available therapy.
Where does retatrutide stand in phase 3 trials and FDA approval?
Phase 3 trials for retatrutide in obesity were initiated following the positive phase 2 data. Phase 3 programs are substantially larger — designed to confirm efficacy in diverse populations and detect rarer adverse events that do not appear in smaller phase 2 cohorts — and typically take 2–4 years to complete and report.
As of mid-2026, retatrutide has not received FDA approval. A New Drug Application (NDA) or Biologics License Application (BLA) would need to be submitted and reviewed following successful phase 3 completion. The FDA review process typically takes 12 months (or less under priority review designation). Even optimistically, commercial availability would be measured in years, not months, from this writing.
Phase 3 safety data — particularly regarding the elevated heart rate signal and long-term cardiovascular outcomes — will be closely scrutinized by the FDA before any approval decision.
Can you legally access retatrutide today?
No. Retatrutide is not available through any legal access path for patients outside of authorized clinical trials. Specifically:
- Not available at compounding pharmacies: Licensed 503A compounding pharmacies in the USA cannot compound investigational drugs for general patient use. Compounding is permitted for drugs with established safety profiles and specific compounding criteria, not for investigational new drugs in clinical development.
- Not available via telehealth: No US-licensed telehealth platform can prescribe retatrutide. It has no approved indication and no prescribable form.
- Gray-market sources: Research chemical suppliers and overseas vendors may list “retatrutide” for sale. These products are unregulated, unverified in identity and purity, and carry significant risk. Their use is not medically supervised. PepScribe strongly advises against obtaining any peptide or investigational drug from unregulated sources.
If you are interested in GLP-1 weight management therapy that is currently accessible, compounded semaglutide and compounded tirzepatide are available through PepScribe’s clinician-supervised protocols, compounded by licensed USA 503A pharmacies with no hidden overseas supply chain.
How does retatrutide compare to currently available options?
Comparing phase 2 retatrutide data to phase 3 tirzepatide data involves significant methodological caveats — different trial designs, durations, and populations make direct numerical comparison unreliable. What can be said:
The phase 2 retatrutide data suggests the triple mechanism may produce a larger average weight reduction than tirzepatide at comparable timepoints. Whether that advantage holds in larger, longer phase 3 trials — and whether the safety profile (particularly the heart rate signal) is acceptable to regulators — remains to be established.
For patients who cannot wait for a drug that may be years from approval, tirzepatide and semaglutide both have robust phase 3 efficacy data, FDA approvals for relevant indications, and established compounding access. The best medication is the one that is available, clinically appropriate for your history, and properly supervised.
Common questions about retatrutide
What is retatrutide (reta peptide)?
Retatrutide is an investigational triple-agonist peptide that activates three receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. It is being investigated by Eli Lilly as a potential treatment for obesity. It has not received FDA approval as of this writing.
How is retatrutide different from tirzepatide or semaglutide?
Semaglutide is a GLP-1 receptor agonist only. Tirzepatide adds GIP receptor activation (dual agonist). Retatrutide adds a third: glucagon receptor activation. Glucagon receptor activity may increase resting energy expenditure, which is theorized to contribute to its stronger weight-loss signal in phase 2 data. Whether this triple mechanism produces an acceptable safety profile at scale is what phase 3 trials are designed to determine.
Is retatrutide approved by the FDA?
No. As of mid-2026, retatrutide has not received FDA approval. It is in late-stage clinical development. FDA approval, if it occurs, would follow successful completion of phase 3 trials and FDA review — a multi-year process from here.
Can I get retatrutide from a compounding pharmacy?
No. Retatrutide is an investigational drug without FDA approval. Licensed 503A compounding pharmacies cannot compound investigational drugs for patient use outside of authorized clinical trials. It is not currently accessible through legal telehealth channels in the USA.
What will retatrutide be used for if approved?
Based on trial design, the primary target indication is obesity (weight management). Phase 2 data also showed effects on metabolic markers relevant to type 2 diabetes. Final approved indications, if any, would be determined by the completed trial data and FDA review.